Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00883740
Other study ID # A0081165
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2009
Est. completion date June 2010

Study information

Verified date July 2011
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must meet diagnostic criteria for fibromyalgia; - Subjects must report difficulty in maintaining sleep at least 3 times per week and meet Research Diagnostic Criteria (RDC) for insomnia disorder, corroborated by subject diary, and meet PSG inclusion criteria at visit 3. Exclusion Criteria: - History of active sleep disorder other than Research Diagnostic Criteria(RDC) insomnia criteria or any sleep or circadian rhythm disturbance; - Use of medications known to affect sleep wake function by Visit 2; - Involved in night or rotating shift work, or travel across >4 time zones 14 days prior to screening and during study; regular daytime napping - PSG finding of apnea/hypopnea or periodic limb movement with arousal index >10/hr on either night of PSG.

Study Design


Intervention

Drug:
Pregabalin
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
Placebo
Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks

Locations

Country Name City State
Canada Pfizer Investigational Site Calgary Alberta
Canada Pfizer Investigational Site Edmonton Alberta
Canada Pfizer Investigational Site Kelowna British Columbia
Canada Pfizer Investigational Site Kelowna British Columbia
Canada Pfizer Investigational Site Mississauga Ontario
Canada Pfizer Investigational Site Point Edward Ontario
Canada Pfizer Investigational Site Thornhill Ontario
Canada Pfizer Investigational Site Toronto Ontario
Canada Pfizer Investigational Site Toronto Ontario
Canada Pfizer Investigational Site Toronto Ontario
Germany Pfizer Investigational Site Berlin
Germany Pfizer Investigational Site Berlin
Germany Pfizer Investigational Site Berlin
Germany Pfizer Investigational Site Berlin
Germany Pfizer Investigational Site Chemnitz
Germany Pfizer Investigational Site Goeppingen
Germany Pfizer Investigational Site Goeppingen
Germany Pfizer Investigational Site Muenchen
Germany Pfizer Investigational Site Muenchen
Germany Pfizer Investigational Site Schwerin
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Baton Rouge Louisiana
United States Pfizer Investigational Site Beachwood Ohio
United States Pfizer Investigational Site Chicago Illinois
United States Pfizer Investigational Site Cleveland Ohio
United States Pfizer Investigational Site Colorado Springs Colorado
United States Pfizer Investigational Site Columbia South Carolina
United States Pfizer Investigational Site Crestview Hills Kentucky
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site DeLand Florida
United States Pfizer Investigational Site Duncansville Pennsylvania
United States Pfizer Investigational Site Hallandale Beach Florida
United States Pfizer Investigational Site Hattiesburg Mississippi
United States Pfizer Investigational Site Hattiesburg Mississippi
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Louisville Kentucky
United States Pfizer Investigational Site Oklahoma City Oklahoma
United States Pfizer Investigational Site Oklahoma City Oklahoma
United States Pfizer Investigational Site Orange City Florida
United States Pfizer Investigational Site Overland Park Kansas
United States Pfizer Investigational Site Pembroke Pines Florida
United States Pfizer Investigational Site Philadelphia Pennsylvania
United States Pfizer Investigational Site Philadelphia Pennsylvania
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site Raleigh North Carolina
United States Pfizer Investigational Site San Diego California
United States Pfizer Investigational Site South Miami Florida
United States Pfizer Investigational Site Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

United States,  Canada,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wake After Sleep Onset (WASO) at Weeks 5 and 11 WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography [PSG]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording [i.e. awake epoch immediately prior to the end of the recording]) on 2 consecutive nights divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)
Secondary Wake Time During Sleep (WTDS) WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Wake Time After Sleep (WTAS) WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Total Sleep Time (TST) TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Sleep Efficiency (SE) SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Number of Awakenings After Sleep Onset (NAASO 1) NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Number of Awakenings After Sleep Onset (NAASO 2) NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Latency to Persistent Sleep (LPS) LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary WASO by Hour of the Night WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total). Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary WASO by Each Quarter of the Night WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments). Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Slow Wave Sleep (SWS) SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
Secondary Change From Baseline in MOS-SS Sleep Disturbance at Weeks 5 and 11 MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline. Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Secondary Change From Baseline in MOS-SS Sleep Problems Index II Weeks 5 and 11 MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline. Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
Secondary Sleep Quality Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores. Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Secondary Latency of Sleep Onset (LSO) LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ. Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Secondary Daily Pain Score Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores. Daily up to Day 73 or ET
Secondary Subjective Wake After Sleep Onset (sWASO) sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values. Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
Secondary Subjective Total Sleep Time (sTST) sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values. Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A